WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsPacific Biosciences of California (PACB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 12790% more annual revenue ($20.63B vs $160.00M). GEHC leads profitability with a 10.1% profit margin vs 0.0%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

PACB

Avoid

30

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Intrinsic value data unavailable for PACB.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

PACB0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

PACB4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$419.78M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Price/BookValuation
69.5x2/10

Trading at 69.5x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : PACB

Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : PACB

The primary concerns for PACB are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

PACB carries more volatility with a beta of 2.30 — expect wider price swings.

PACB is growing revenue faster at 13.8% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (60/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Pacific Biosciences of California

HEALTHCARE · MEDICAL DEVICES · USA

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.

Want to dig deeper into these stocks?